Biokinetic model for the calculation of dose coefficients for oral and intravenous administration of 14C labeled drugs

被引:0
|
作者
Krins, A. [1 ]
Fidorra, J. [2 ]
Pleiss, U. [3 ]
Sahre, P. [1 ]
Schoenmuth, T. [1 ]
机构
[1] VKTA Verein Kernverfahrenstech & Analyt Rossendor, Nucl Engn & Analyt Rossendorf Inc, Postfach 51 01 19, D-01314 Dresden, Germany
[2] Bayer AG, Radiat Protect, D-51368 Leverkusen, Germany
[3] Bayer AG, Pharma Prod Dev, D-42096 Wuppertal, Germany
关键词
D O I
暂无
中图分类号
TL [原子能技术]; O571 [原子核物理学];
学科分类号
0827 ; 082701 ;
摘要
A first order biokinetic model is presented for the calculation of dose coefficients from human activity excretion data after intravenous and oral administration of C-14 labeled drugs It is intended for the dose estimation in human studies in drug research, where the number of measurements is low and their uncertainty rather high. The model depends on only 6 parameters that are to be adjusted with the help of the measurement data. A comparison of measured and calculated activities in excreta of four human studies on C-14 labeled drugs revealed considerable agreement, although some limitations have to be accepted. In contrast to the biokinetic model for C-14 in organic compounds recommended by the International Commission on Radiological Protection (ICRP) the present model does not assume a fixed biological half-life of 40 days, but follows the experimental data. In consequence, the resulting dose coefficients differ from the ICRP value. For experimental data tested and assuming uniform activity distribution, the committed effective doses amount between one twenty-fifth to one fiftieth of the values calculated from the ICRP model. The uncertainty of the derived dose coefficients is estimated to be about +/- 50 %.
引用
收藏
页码:205 / 213
页数:9
相关论文
共 50 条
  • [1] Biokinetic model for the calculation of dose coefficients for oral and intravenous administration of 14C labeled drugs
    Krins, A
    Fidorra, J
    Pleiss, U
    Sahre, P
    Schönmuth, T
    KERNTECHNIK, 2003, 68 (5-6) : 205 - 213
  • [2] 14C dose coefficients
    Killough, GG
    Rohwer, PS
    HEALTH PHYSICS, 2006, 90 (03): : 273 - 275
  • [3] Pharmacokinetics of [14C]-atrazine in rhesus monkeys, single-dose intravenous and oral administration
    Hui, Xiaoying
    Wester, Ronald C.
    Maibach, Howard I.
    TOXICOLOGICAL AND ENVIRONMENTAL CHEMISTRY, 2011, 93 (02): : 370 - 382
  • [4] Biotransformation of [14C]-phenylbutazone after oral or intravenous administration to cattle.
    Smith, D
    Huwe, JK
    Lorentzsen, M
    Harrington, GE
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2004, 228 : U103 - U103
  • [5] Pharmacokinetics of [14C]Ciclesonide After Oral and Intravenous Administration to Healthy Subjects
    Ruediger Nave
    Thomas D. Bethke
    Sjoerd P. van Marle
    Karl Zech
    Clinical Pharmacokinetics, 2004, 43 : 479 - 486
  • [6] Pharmacokinetics of [14C]ciclesonide after oral and intravenous administration to healthy subjects
    Nave, R
    Bethke, TD
    van Marle, SP
    Zech, K
    CLINICAL PHARMACOKINETICS, 2004, 43 (07) : 479 - 486
  • [7] Metabolism and disposition of [14C]dibromoacetonitrile in rats and mice following oral and intravenous administration
    Mathews, J. M.
    Pulliam, D., Jr.
    Black, S. R.
    Burka, L. T.
    XENOBIOTICA, 2010, 40 (07) : 499 - 509
  • [8] 14C dose coefficients -: Response to Killough and Rohwer
    Moeller, DW
    Ryan, MT
    Sun, LSC
    Cherry, RN
    HEALTH PHYSICS, 2006, 90 (03): : 275 - 276
  • [9] THE METABOLIC DISPOSITION OF C-14-LABELED CARMOISINE IN THE RAT AFTER ORAL AND INTRAVENOUS ADMINISTRATION
    GALLI, CL
    MARINOVICH, M
    COSTA, LG
    FOOD AND CHEMICAL TOXICOLOGY, 1982, 20 (04) : 351 - 356
  • [10] Pharmacokinetics and ADME Characterization After Oral and Intravenous Administration of [14C]-Ziftomenib in Healthy Male Participants
    Mitra, Amitava
    Ahsan, Julie Mackey
    Tabachri, Marilyn
    El-Shahat, Taha
    Leoni, Mollie
    Dale, Stephen
    CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2025, 18 (02):